Epstein-Barr virus (EBV) can be reactivated by biological agents such as bacteria and viruses, leading to various pathologies. EBV is a common human virus that infects epithelial cells and B lymphocytes, and can remain latent in the body. However, under certain conditions, such as immunosuppression or stress, the virus can reactivate and cause chronic infections. The reactivation of EBV is associated with various diseases, including Burkitt's lymphoma, Hodgkin's disease, and AIDS-associated lymphoblastoma. Several bacteria, such as Aggregatibacter actinomycetemcomitans, Porphyromonas gingivalis, and Helicobacter pylori, have been shown to induce EBV reactivation. These bacteria can cause DNA damage, activate signaling pathways, and trigger the expression of EBV lytic genes. Additionally, viruses such as HSV-1, HHV-6, HCMV, HIV, and SARS-CoV-2 have also been reported to cause EBV reactivation. These viruses can modulate the host environment, activate transcription factors, and promote the lytic cycle of EBV. EBV reactivation can lead to severe complications, including lymphoproliferative diseases and increased risk of cancer. The reactivation of EBV is often associated with immunosuppression, and the mechanisms involved are complex and not fully understood. However, studies have shown that EBV reactivation can be influenced by various factors, including bacterial infections, viral infections, and immune dysfunction. Understanding the mechanisms of EBV reactivation by biological agents is crucial for developing strategies to prevent and treat EBV-related diseases.Epstein-Barr virus (EBV) can be reactivated by biological agents such as bacteria and viruses, leading to various pathologies. EBV is a common human virus that infects epithelial cells and B lymphocytes, and can remain latent in the body. However, under certain conditions, such as immunosuppression or stress, the virus can reactivate and cause chronic infections. The reactivation of EBV is associated with various diseases, including Burkitt's lymphoma, Hodgkin's disease, and AIDS-associated lymphoblastoma. Several bacteria, such as Aggregatibacter actinomycetemcomitans, Porphyromonas gingivalis, and Helicobacter pylori, have been shown to induce EBV reactivation. These bacteria can cause DNA damage, activate signaling pathways, and trigger the expression of EBV lytic genes. Additionally, viruses such as HSV-1, HHV-6, HCMV, HIV, and SARS-CoV-2 have also been reported to cause EBV reactivation. These viruses can modulate the host environment, activate transcription factors, and promote the lytic cycle of EBV. EBV reactivation can lead to severe complications, including lymphoproliferative diseases and increased risk of cancer. The reactivation of EBV is often associated with immunosuppression, and the mechanisms involved are complex and not fully understood. However, studies have shown that EBV reactivation can be influenced by various factors, including bacterial infections, viral infections, and immune dysfunction. Understanding the mechanisms of EBV reactivation by biological agents is crucial for developing strategies to prevent and treat EBV-related diseases.